AskAt received a notice from RMX Pharmaceutical Technology Co., Ltd., (Headquartered in Hangzhou, China; CEO, RuiPing Dong; “RMX”) that on Oct 27, 2019, RMX initiated a Phase I clinical study of AAT-076 in the People’s Republic of China (China). AAT-076 is a new generation COX-2 inhibitor that has already demonstrated excellent safety and efficacy profile for post-operative pain in human studies in the US. AskAt will receive a milestone payment from RMX in conjunction with the initiation of the study in China.